ObsEva (NASDAQ:OBSV) Earns Hold Rating from Analysts at StockNews.com

Equities researchers at StockNews.com started coverage on shares of ObsEva (NASDAQ:OBSVGet Rating) in a research report issued to clients and investors on Friday. The firm set a “hold” rating on the stock.

Other analysts also recently issued reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $11.00 price objective on shares of ObsEva in a report on Tuesday, June 21st. Canaccord Genuity Group began coverage on shares of ObsEva in a report on Tuesday, April 26th. They issued a “buy” rating and a $12.00 price objective on the stock. Cantor Fitzgerald downgraded shares of ObsEva from an “overweight” rating to a “neutral” rating in a report on Thursday, July 28th. Finally, Canaccord Genuity Group downgraded shares of ObsEva from a “buy” rating to a “hold” rating and lowered their target price for the stock from $12.00 to $1.00 in a report on Monday. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, ObsEva presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.50.

ObsEva Price Performance

NASDAQ OBSV opened at $0.27 on Friday. The company has a quick ratio of 3.09, a current ratio of 3.09 and a debt-to-equity ratio of 1.18. ObsEva has a 12-month low of $0.22 and a 12-month high of $3.35. The company has a market capitalization of $21.05 million, a PE ratio of -0.42 and a beta of 0.20. The firm’s 50 day moving average is $1.57 and its 200-day moving average is $1.48.

ObsEva (NASDAQ:OBSVGet Rating) last posted its quarterly earnings data on Tuesday, May 17th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.11. The business had revenue of $2.24 million during the quarter. Equities research analysts anticipate that ObsEva will post -0.75 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ObsEva

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OBSV. Bank of America Corp DE boosted its position in ObsEva by 54,142.2% during the first quarter. Bank of America Corp DE now owns 484,383 shares of the company’s stock worth $731,000 after purchasing an additional 483,490 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in ObsEva by 15.6% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 668,485 shares of the company’s stock worth $1,009,000 after purchasing an additional 90,359 shares during the period. Banque Pictet & Cie SA bought a new position in ObsEva during the first quarter worth $83,000. Cutter & CO Brokerage Inc. boosted its position in shares of ObsEva by 15.9% in the first quarter. Cutter & CO Brokerage Inc. now owns 206,200 shares of the company’s stock valued at $311,000 after acquiring an additional 28,250 shares during the period. Finally, XTX Topco Ltd boosted its position in shares of ObsEva by 33.9% in the first quarter. XTX Topco Ltd now owns 79,757 shares of the company’s stock valued at $120,000 after acquiring an additional 20,196 shares during the period. 27.80% of the stock is owned by institutional investors.

About ObsEva

(Get Rating)

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women.

Read More

Analyst Recommendations for ObsEva (NASDAQ:OBSV)

Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.